Table 1: Demographic, clinical, and therapeutic
characteristics.
|
|
MT-group (n = 12) |
Control-group (n = 12) |
|
Age
(years) |
46.2 |
47.2 |
|
Male/female |
n = 4/n
= 8 |
n = 6/n
= 6 |
|
HLA-B27
positive |
n = 10 |
n = 6 |
|
Disease
duration (years) |
6.3 |
9.0 |
|
BASDAI |
5.43 ±
2.58 |
5.32 ±
2.07 |
|
BASFI |
4.53 ±
2.27 |
4.94 ±
2.87 |
|
BAS-G |
6.79 ±
1.67 |
6.29 ±
1.86 |
|
Morning
stiffness (hours) |
1 ± 0.7 |
0.77 ±
0.75 |
|
Peripheral
arthritis |
n = 5 |
n = 8 |
|
Enthesitis |
n = 3 |
n = 7 |
|
Iritis |
n = 3 |
n = 4 |
|
Medication |
||
|
NSAIDs |
n = 11 |
n = 10 |
|
DMARDs |
n = 5 |
n = 8 |
MT:
manual therapy; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index;
BASFI: Bath Ankylosing Spondylitis
Disease Functional Index;
BAS-G:
Bath Ankylosing Spondylitis Patient Global Score; NSAIDs: nonsteroidal
antiinflammatory rheumatic drugs, DMARDs: Disease-modifying antirheumatic drugs